MarketInOut Stock Screener Log In | Sign Up

Atea Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/06/2026
Atea Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization357.71 mln
Float63.79 mln
Earnings Date11/09/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

8.50
Transformational upside

Relative Strength

89 / 100
Strongly outperforming

Debt / Equity

0.00
Debt-free

ROE

-59.31
Deeply negative

ROA

-53.35
Deeply negative

Business Description

Atea Pharmaceuticals is a Boston-based company focused on developing oral medicines to treat serious viral infections. Its most advanced treatment combines two drugs, bemnifosbuvir and ruzasvir, currently in late-stage clinical trials for hepatitis C, while a separate drug for chronic hepatitis E is in earlier testing. The company works with MSD International GmbH to develop and bring ruzasvir to market.

Key Fundamentals

EPS-2.13
ROE-59.31
ROIC-1,793
ROA-53.35
EBITDA, mln-171
EV / EBITDA-0.67
EV / EBIT-0.67

Quote Details

Last 4.31
Change 0.09 (2.13%)
Open 4.21
Volume 199,472
Turnover 859,724
Average Volume 303,685

Financial Ratios

Leverage Ratio1.14
Current Ratio8.13
Price / Book1.64
Price / Tangible Book1.64
Debt / Equity0.00

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price8.50
Short Ratio10.36
Short % of Float4.94

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 4.87% 89 / 100   
1 Month -16.47% 24 / 100   
2 Months -6.51% 43 / 100   
6 Months -20.63% 28 / 100   
1 Year 33.02% 88 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog